Inhibition of human LDL oxidation by the neuroprotective drug l-deprenyl

References

• Goldstein JL, Brown MS. The low density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Biochem 1997; 46: 897–930
   Google Scholar
• Steinberg D. Lipoproteins and atherosclerosis: A look back and a look ahead. Atherosclerosis 1983; 3: 283–301
   Google Scholar
• Steinberg D, Parthasarathy 5, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenecity. N Eng J Med 1989; 230: 915–924
   Google Scholar
• Holvoet P, Collen D. Oxidation of low density lipoproteins in the pathogenesisof atherosclerosis. Atherosclerosis Atherosclerosis; 137 (Suppl.): 533-538
   Google Scholar
• Pal inski W, Rosenfeld ME, Yla-Herttuala 5, Gurtner GC, Socher SS, Butler SW, Parthasarathy 5, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative-modification in vivo. Proc Natl Acad Sci USA 1989; 86: 1372-1376
   Google Scholar
• Palinski W, Horkko 5, Miller E, et al. Cloning of monoclonal antibodiesto epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice — demonstration of epitopes of oxidized low density lipoprotein in human plasma. I Clin Invest 1996; 98: 800–814
   PubMed Web of Science ®Google Scholar
• Yla-Herttuala 5, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbits and man. Clin Invest 1989; 84: 1086–1095
   Google Scholar
• Boyd HC, Gown AM, Wolfbauer G, Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol 1989; 1 35: 815–825
   Google Scholar
• Palinswki WS, Yla-Herttuala 5, Rosenfeld ME, Butler SW, Socher SS, Parthasarathy 5, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Atherosclerosis 1990; 10: 325–335
   Google Scholar
• Rijke YB, de Verwey HF, Vojelezang CJM, et al. Enhanced susceptibility of low density lipoproteins to oxidation in coronary bypass patients with progression of atherosclerosis. Clin Chim Acta 1995; 243: 137–149
   PubMed Web of Science ®Google Scholar
• Princen HMG, Van Duyvenvoorde W, Buytenhek R, et al. Supplementation with low doses of vitamin E protects low density lipoproteins from lipid peroxidation in men and women. Arterioscler Thrombo Vasc Blot 1995; 15: 325–333
   PubMed Web of Science ®Google Scholar
• Heller FR, Descamps O, Hondekijn JC. LDL oxidation:Therapeutic perspectives. Atherosclerosis 1998; 137 (Su ppl.): S25-531
   Google Scholar
• Sparrow CP, Parthasarathy 5, Steinberg D. A macrophage receptor that recognizes oxidized lipoproteins, but not acetylated low density lipoproteins. J Biol Chem 1989; 264: 2599–2604
   PubMed Web of Science ®Google Scholar
• Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G. A new function for LDL receptor: Transcytosis of LDL across the blood—brain barrier. J Cell Biol 1997; 138: 877–889
   PubMed Web of Science ®Google Scholar
• Sugawa M, Ikeda 5, Kushima Y, Takshima Y, Cynshi O. Oxidized LDL caused CNS neuron cell death. Brain Res 1997; 761: 165–172
   PubMed Web of Science ®Google Scholar
• Moroney JT, Tang M, Berglund L, Small 5, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999; 282: 254–260
   PubMed Web of Science ®Google Scholar
• Vyas 5, Gangar K. Postmenopausal estrogens and arteries. Br J Obstet Gynaecol 1995; 192: 942–946
   Google Scholar
• Aviram M, Fuhrman B. Polyphenolic flavinoids inhibit macro-phage-mediated oxidation of LDL and attenuate atherogenesis. Atheroscierosis Atheroscierosis; 137 (Suppl.): S45-550
   Google Scholar
• The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Eng J Med 1993; 328: 175–183
   Google Scholar
• Sano M, Ernesto C, Thomas RG, et al. A controlled trial of Selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Eng J Med 1997; 336: 1216–1221
   PubMed Web of Science ®Google Scholar
• Birkmayer WJ, Knoll P, Riederer P. Increasing life expectancy resulting from adidtion of L-deprenyl to Madopar treatment in Parkinson's disease: A long-term study. J Neurol Transm 1985; 64: 113–127
   PubMed Web of Science ®Google Scholar
• Knoll J, Dallo J, Yan TT. Striata I dopamine, sexual activity and life span. Longevity of rats treated with L-deprenyl. Mech Ageing Dev 1989; 46: 525–532
   Google Scholar
• Thomas T, McLendon C, Thomas G. L-deprenyl, nitric oxide production and dilation of cerebral blood vessels. NeuroReport 1998; 9: 2595–2600
   PubMed Web of Science ®Google Scholar
• Thomas T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol Aging 2000; 21: 343–348
   PubMed Web of Science ®Google Scholar
• Malsberg B. Mortality among patients with involution melancholia. Am J Psychiatry 1937; 93: 1231-1238
   Google Scholar
• Rosanski A, Blumenthal AJ, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implica-tions for therapy. Circulation 1999; 99: 2192–2217
   PubMed Web of Science ®Google Scholar
• Roose SP, Devanand D, Suthers K. Depression: Treating the patient with comorbid cardiac disease. Geriatrics 1999; 54: 20–35
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis— An inflammatory disease. N Eng J Med 1999; 340: 115–121
   PubMed Web of Science ®Google Scholar
• Thomas T, Sutton ET, Bryant MW, Rhodin JAG. In vivo vascular damage, leukocyte activation and inflammatory response induced by fl-amyloid. J Submicrosc Cytol Pathol 1997; 29: 293-304
   Google Scholar
• Kleinveld HA, Hak-Lemmers HLM, Stalenhoef AFH, Demacker PNM. Improved measurement of low-density lipoprotein suscept-ibility to copper-induced oxidation. Application of a short procedure for isolating low density lipoprotein. Clin Chem 1992; 38: 2066–2072
   PubMed Web of Science ®Google Scholar
• Chung BH, Segrest JP, Ray MJ, Brunzell JD, Hokanson JE, Krauss RM, Beaudrie K, Cone JT. Single vertical spin density gradient u ltracentrifugation . Meth Enzym 1986; 128: 181–209
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall AJ. Protein measure-ment with fo lin phenol reagent. JBiol Chem 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low-density lipoprotein. Free Radic Res Commun 1989; 6: 67–75
   PubMed Web of Science ®Google Scholar
• Beuge A, Aust SD. Microsomal lipid peroxidation. Meth Enzym 1981; 52: 302–310
   Google Scholar
• Parthasarathy 5, Fong LG, Quinn MT, Steinberg D. Oxidative modification of LDL: Comparison between cell-mediated and copper-mediated modification. Eur Heart J 1990; 11: 83–87
   PubMed Web of Science ®Google Scholar
• Noguchi N, Niki E. Dynamics of vitamin E action against LDL oxidation. Free Rad Res 1998; 28: 561–572
   PubMed Web of Science ®Google Scholar
• Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S. Inhibition of LDL oxidation by nitric oxide. FEBS 1993; 334: 170-174
   Google Scholar